grant
Cholinergic Dysfunction in Glaucoma
Organization STANFORD UNIVERSITYLocation STANFORD, UNITED STATESPosted 30 Sept 2025Deadline 31 Mar 2030
NIHUS FederalResearch GrantFY202521+ years oldAccelerationAdultAdult HumanAnimal ModelAnimal Models and Related StudiesAnimalsAxonBehaviorBehavior assessmentBiologic ModelsBiological ModelsBlindnessBlood VesselsBrainBrain Nervous SystemCell Communication and SignalingCell NucleusCell SignalingCell membraneCholineChronicClinicalCommon Rat StrainsCranial Nerve IICytoplasmic MembraneDependenceDeteriorationDevelopmentDiminished VisionDiseaseDisease ProgressionDisorderDoppler OCTDoseDysfunctionEncephalonEnvironmentExperimental Animal ModelExperimental ModelsExperimental TherapiesEyeEyeballFunctional disorderFunctional impairmentFutureGlaucomaGoalsHistologicHistologicallyHumanHydrogelsImpairmentInjectionsIntermediary MetabolismInterventionIntracellular Communication and SignalingIntraocular PressureInvestigational TherapiesInvestigational TreatmentsKnowledgeLesionLong-Evans RatsLow VisionMR ImagingMR TomographyMRIMRIsMagnetic Resonance ImagingMeasuresMediatingMedical Imaging, Magnetic Resonance / Nuclear Magnetic ResonanceMetabolicMetabolic ProcessesMetabolismModel SystemModelingModern ManMonitorNMR ImagingNMR TomographyNerve DegenerationNerve Impulse TransmissionNerve TransmissionNervous SystemNeurologic Body SystemNeurologic Organ SystemNeurologic ProcessNeuron DegenerationNeuronal TransmissionNuclear Magnetic Resonance ImagingNucleusOCT TomographyOcular TensionOptic NerveOptic TractsOptic tract structureOptical Coherence TomographyOralOutcomeOutcome AssessmentPOAGPartial SightPathogenesisPathogenicityPathway interactionsPatientsPerimetryPhysiologic Intraocular PressurePhysiopathologyPlasma MembranePrimary Open Angle GlaucomaProbabilistic ModelsProbability ModelsProcessRatRats MammalsRattusReduced VisionRetinaRisk FactorsRodent ModelRoleSecond Cranial NerveSeveritiesSeverity of illnessSightSignal TransductionSignal Transduction SystemsSignalingSourceSpectroscopySpectrum AnalysesSpectrum AnalysisStatistical ModelsStructureSubnormal VisionSupplementationSystemTechniquesTestingTherapeuticTimeTranslational ResearchTranslational ScienceTreatment outcomeValidationVisionVisualVisual FieldsVisual PathwaysVisual SystemVisual impairmentZeugmatographyadulthoodaxon signalingaxon-glial signalingaxonal signalingbasal forebrainbehavioral assessmentbiological signal transductionbrain MR imagingbrain MRIbrain magnetic resonance imagingcerebral MR imagingcerebral MRIcerebral magnetic resonance imagingcholine supplementationcholinergiccholinergic neuronclinical applicabilityclinical applicationclinical translationclinically translatablecomparator groupcomparison groupdemographicsdevelopmentaldisease severityexperimentexperimental researchexperimental studyexperimental therapeutic agentsexperimental therapeuticsexperimentseye fieldglaucomatousglia signalingglial signalingimaging approachimaging based approachimprovedin vivointra-ocular pressuremalleable riskmodel of animalmodifiable risknerve signalingneuralneural controlneural degenerationneural regulationneural signalingneurobehavioralneurochemicalneurochemistryneurodegenerationneurodegenerativeneuroimaging biomarkerneuroimaging markerneurological degenerationneuromodulationneuromodulatoryneuronal degenerationneuronal signalingneuroregulationneurotransmissionnon-invasive imagingnoninvasive imagingnoveloptical Doppler tomographyoptical coherence Doppler tomographypathophysiologypathwayplasmalemmapre-clinicalpre-clinical studypreclinicalpreclinical studypreservationresponsesocial rolespatial and temporalspatial temporalspatiotemporalstatistical linear mixed modelsstatistical linear modelssupplementation with cholinetonometrytranslation researchtranslational applicationstranslational investigationvalidationsvascularvision impairmentvision lossvisual functionvisual lossvisually impaired
Description preview
Although intraocular pressure (IOP) is the only clinically modifiable risk factor for glaucoma, the exact role of IOP
elevation in glaucomatous neurodegeneration is unclear, as the cause of glaucoma remains unknown. Even
worse, glaucoma may progress in patients under controlled IOP, indicating that additional factors are pivotal to
its…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click